Dubai: The Emirates Drug Establishment (EDE) has announced the registration of Blenrep (Belantamab Mafodotin) as an ...

GSK (NYSE:GSK) announced on Monday that the U.S. FDA has granted priority review for its marketing application, aimed at ...

Blenrep approved in the EU for multiple myeloma | Regulatory NewsThe approval is based on superior efficacy results demonstrated by Blenrep combinations in the pivotal DREAMM-7 and DREAMM-8 phase ...

GSK is sticking to its projection to generate more than 40 billion pounds of sales in 2031, regardless of whether it regains U.S. approval of Blenrep.

Blenrep combinations consistently benefited a broad range of patients, including those with poor prognostic features or outcomes, such as high-risk cytogenetics or those refractory to lenalidomide.

GSK’s Blenrep is the only B-cell maturation antigen-targeted antibody-drug conjugate approved for multiple myeloma, offering patients a differentiated mechanism of action. Blenrep combinations can ...

In Canada, Blenrep (belantamab mafodotin for injection) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and dexamethasone, or in combination with pomalidomide and dexamethasone ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

Blenrep US ODAC outcome | Regulatory NewsGSK remains confident in the benefit/risk profile of Blenrep (belantamab mafodotin-blmf) and will continue to work closely with the FDA as they complete ...

GSK plc announced the approval of Blenrep combinations by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma. The approval ...